Abstract: Objective To explore the post-marketing adverse reactions of two Chikungunya vaccines-the live attenuated vaccine IXCHIQ and the virus-like particle vaccine VIMKUNYA-and related mechanisms in order to contribute to the development and applications of Chikungunya vaccines in the future. Methods Such databases as PubMed, ScienceDirect and CNKI were searched for information on the marketing and adverse reactions of Chikungunya vaccines before the adverse reactions and related mechanisms were compared and analyzed. Results The post-marketing adverse reactions of the live attenuated vaccine IXCHIQ included fever, joint pain, headache and myalgia, and pain at the site of injection, which were related to such mechanisms as exposures to antigens, high expressions of Mxra8 receptor, and increased inflammatory mediators. Dozens of serious adverse events were reported that involved the cardiovascular and nervous systems, and were believed to be linked to direct infections, immune mediation, and amplification of NLRP3 inflammasomes. VIMKUNYA, a virus-like particle vaccine, was put on markets not long ago, so there were relatively few reports of adverse reactions, including fever, syncope, fatigue, headache, myalgia and joint pain. Conclusion The clinical use of the live attenuated vaccine IXCHIQ requires vigilance about serious adverse reactions. The data on safety of the virus-like particle vaccine VIMKUNYA needs to be monitored all the time.

Key words: Chikungunya Virus (CHIKV) Vaccines, IXCHIQ, VIMKUNYA, Adverse Drug Reaction, Mechanisms, Safety Monitoring